Elanco Animal Health Incorporated (NYSE:ELAN) Receives Consensus Recommendation of “Hold” from Analysts

Elanco Animal Health Incorporated (NYSE:ELAN) has been assigned an average rating of “Hold” from the seven research firms that are presently covering the stock, Marketbeat.com reports. Four investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $15.17.

Several analysts have weighed in on the company. Piper Sandler cut their price objective on Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a research report on Thursday, March 6th. Stifel Nicolaus upped their price objective on Elanco Animal Health from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Monday. UBS Group dropped their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a report on Wednesday, February 26th. Barclays decreased their target price on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Finally, Morgan Stanley decreased their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 26th.

Insider Buying and Selling

In other Elanco Animal Health news, Director Lawrence Erik Kurzius acquired 10,000 shares of the company’s stock in a transaction dated Tuesday, March 11th. The stock was acquired at an average cost of $10.20 per share, with a total value of $102,000.00. Following the purchase, the director now directly owns 111,459 shares in the company, valued at approximately $1,136,881.80. This trade represents a 9.86% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 0.89% of the stock is owned by company insiders.

Hedge Funds Weigh In On Elanco Animal Health

A number of hedge funds have recently made changes to their positions in ELAN. FMR LLC increased its position in shares of Elanco Animal Health by 1,153.6% in the 4th quarter. FMR LLC now owns 40,232,327 shares of the company’s stock worth $487,213,000 after purchasing an additional 37,022,891 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Elanco Animal Health in the 1st quarter valued at approximately $115,212,000. Norges Bank purchased a new stake in shares of Elanco Animal Health in the 4th quarter valued at approximately $47,424,000. Dimensional Fund Advisors LP increased its stake in Elanco Animal Health by 14.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company’s stock valued at $214,875,000 after buying an additional 2,563,740 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after buying an additional 2,445,872 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Stock Performance

Shares of Elanco Animal Health stock opened at $13.24 on Thursday. Elanco Animal Health has a 52 week low of $8.02 and a 52 week high of $18.80. The company has a market cap of $6.58 billion, a PE ratio of 33.10, a price-to-earnings-growth ratio of 2.50 and a beta of 1.49. The business has a 50 day moving average price of $10.16 and a 200-day moving average price of $11.44. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.06. The firm had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business’s revenue for the quarter was down 1.0% on a year-over-year basis. During the same period last year, the company earned $0.34 earnings per share. Equities analysts anticipate that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.